A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

PURPOSE: To evaluate whether adding humanized monoclonal insulin growth factor-1 receptor (IGF-1R) antibody (dalotuzumab) to mammalian target of rapamycin (mTOR) inhibitor (ridaforolimus) plus aromatase inhibitor (exemestane) improves outcomes in patients with estrogen receptor (ER)-positive advance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Rugo, Hope S., Trédan, Olivier, Ro, Jungsil, Morales, Serafin M., Campone, Mario, Musolino, Antonino, Afonso, Noémia, Ferreira, Marta, Park, Kyong Hwa, Cortes, Javier, Tan, Antoinette R., Blum, Joanne L., Eaton, Lamar, Gause, Christine K., Wang, Zhen, Im, Ellie, Mauro, David J., Jones, Mary Beth, Denker, Andrew, Baselga, José
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5709225/
https://ncbi.nlm.nih.gov/pubmed/28681171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4375-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados